Live feed18:13:00·1905dPRReleasevia QuantisnowImmunityBio and NantKwest Announce FDA Authorization to Study hAd5 T-Cell COVID-19 Vaccine for Combination of Subcutaneous, Oral and Sublingual Boost to Induce T-Cell, Mucosal, and Antibody ImmunityByQuantisnow·Wall Street's wire, on your screen.NK· NantKwest, Inc.Health CareOriginal source
